Metformin versus Clomiphene Citrate or a Combination of Both as First-Line Therapy in Afertile Anovulatory Women with PCOS by Kinzler, Camille
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
8-15-2009
Metformin versus Clomiphene Citrate or a
Combination of Both as First-Line Therapy in
Afertile Anovulatory Women with PCOS
Camille Kinzler
Pacific University
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Kinzler, Camille, "Metformin versus Clomiphene Citrate or a Combination of Both as First-Line Therapy in Afertile Anovulatory
Women with PCOS" (2009). School of Physician Assistant Studies. Paper 164.
Metformin versus Clomiphene Citrate or a Combination of Both as First-
Line Therapy in Afertile Anovulatory Women with PCOS
Abstract
Background: Clomiphene citrate has been used as first-line therapy to enhance fertility in anovulatory afertile
women with or without polycystic ovarian syndrome for forty years. Women with PCOS have a higher
propensity to develop metabolic syndrome and infertility. Therefore, a secondary outcome in treating
anovulatory afertile women with metformin, may be to delay the development of type 2 diabetes plus induce
ovulation and achievement of pregnancy.
Methods: The focus of this study was to review the current literature on all studies pertaining to the first-line
treatment of anovulatory afertile women with PCOS, by comparing the clomiphene citrate to metformin to
induce ovulation and achieve pregnancy. The treatments reviewed included metformin, extended release
metformin, clomiphene citrate or a combination of both metformin and clomiphene citrate.
Results: Of the 5 studies published, 2 studies still considered clomiphene citrate to be superior to metformin
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clomiphene citrate and one study considered both to be acceptable first-line treatment options.
Conclusion: Clomiphene citrate should still be considered first-line therapy for the treatment of inducing
ovulation and achieving pregnancy in anovulatory infertile women with PCOS. However, further randomized,
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Abstract   
 
Background:  Clomiphene citrate has been used as first-line therapy to enhance fertility in 
anovulatory afertile women with or without polycystic ovarian syndrome for forty years. Women with 
PCOS have a higher propensity to develop metabolic syndrome and infertility. Therefore, a secondary 
outcome in treating anovulatory afertile women with metformin, may be to delay the development of 
type 2 diabetes plus induce ovulation and achievement of pregnancy.  METHODS: The focus of this 
study was to review the current literature on all studies pertaining to the first-line treatment of 
anovulatory afertile women with PCOS, by comparing the clomiphene citrate to metformin to induce 
ovulation and achieve pregnancy. The treatments reviewed included metformin, extended release 
metformin, clomiphene citrate or a combination of both metformin and clomiphene citrate. 
RESULTS: Of the 5 studies published, 2 studies still considered clomiphene citrate to be superior to 
metformin at inducing ovulation and achieving pregnancy at 6 months, two studies considered 
metformin superior to clomiphene citrate and one study considered both to be acceptable first-line 
treatment options. CONCLUSION:  Clomiphene citrate should still be considered first-line therapy 
for the treatment of inducing ovulation and achieving pregnancy in anovulatory infertile women with 
PCOS. However, further randomized, blinded studies are needed to better substantiate metformin’s 
long term (>6 months) use and secondary benefit of decreasing the likelihood of acquiring type 2 
diabetes and other sequelae. KEYWORDS:  metformin, infertility, PCOS, pregnancy, clomiphene, 
ovulation  
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Metformin versus Clomiphene Citrate or a Combination of Both as First-Line 
Therapy in Afertile Anovulatory Women with PCOS 
Introduction 
 
Polycystic ovarian syndrome (PCOS) affects 7%-8% of women1 in the general US population 
and is one of the most common causes of anovulatory infertility, at a rate of about 5%-10% of women 
of reproductive age.2 The Rotterdam diagnostic criteria of 2003 define PCOS as a syndrome consisting 
of two out of the three following disorders: chronic anovulation, clinical and/or biochemical evidence 
of hyperandrogenism and polycystic ovaries.3 Controversy exists surrounding both diagnosis and 
treatment of this disorder.1 It is unclear whether a woman with hyperandrogenism and polycystic 
ovaries who has a regular menstrual cycle should be included in the definition, or conversely, if an 
anovulatory women with polycystic ovaries without hyperandrogenism should be included.3 
The purpose of this systematic review is to decide whether metformin should be used as a first-line 
treatment in the induction of ovulation and the achievement of pregnancy in anovulatory infertile 
women with PCOS. 
In 19th century scientific publications, references were made to what we now understand as 
PCOS. However, the syndrome was not described until 1935, in a paper by Stein and Leventhal. The 
combination of anovulation and excess androgen were common findings in polycystic ovarian 
morphology and remained the mainstay for the next half century. The National Institute of Health met 
in 1990 to re-define PCOS as chronic anovulation associated with clinical and/or biochemical evidence 
of androgen excess in the absences of other pathologies. 3 Hirsutism, acne, or male-pattern baldness 
clinically define hyperandrogenism 4 and high serum levels of androgen define biochemical 
hyperandrogenemia.8
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 Anovulation can either manifest as infertility, oligomenorrhea, or amenorrhea. 
Abnormally regulating luteinizing hormone (LH) was thought to be the sole reason for these 
symptoms, but now studies indicate insulin resistance and hyperinsulinemia may play a role.4  More 
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recent studies have shown a connection between polycystic ovaries in women who have normal 
menses, but have biochemical features of PCOS. These women tend to have less insulin resistance and 
hyperinsulinemia than those with chronic anovulation.3 
Obesity is associated with increased insulin resistance and therefore can cause chronic 
anovulation 4, which means obese women with PCOS are more likely to be anovulatory than lean, 
hyperandrogenemic women.3 Fifty percent of obese women who lose 5%-10% of their body weight 
over six months reestablish ovarian function. Recent evidence has shown that hyperinsulinemia and 
insulin resistance increase circulating ovarian androgen concentrations, thus impeding ovulation.4 
Insulin-lowering and insulin-sensitizing medications have beneficial effects on ovulation and fertility 
in obese women with PCOS, as do diet and lifestyle modifications. This suggests a link between 
metabolic disturbances and ovulation.3 The exact mechanism of insulin resistance in PCOS remains 
unclear 4. The metabolic disturbances associated with PCOS 3 are a potential health hazard with long-
term sequelae including type 2 diabetes, cardiovascular disease and hyperlipidemia.5 
PCOS has been associated with anovulation, obesity, hyperandrogenism, insulin resistance with 
compensatory hyperinsulinemia, ovarian morphologic changes, and hypergonadotropin secretion 
(particularly elevated LH), all of which can secondarily cause female infertility and pregnancy 
complications.1 Infertility occurs in about 75% of women who have polycyctic ovarian syndrome. 
Anovulation is the primary reason this occurs.4  Early pregnancy loss is about 10% to 15% in normal 
pregnancy and is higher in women with PCOS. Pregnancy loss in women with PCOS may be due to 
elevated plasma LH levels, hyperandrogenemia, and high plasminogen activator inhibitor, although the 
most compelling hypothesis is contributed to obesity. Insulin resistance increases in normal pregnancy, 
and therefore may “augment the preexisting insulin resistance and hyperinsulinemia” in women with 
PCOS resulting in spontaneous abortion.4 
 The lab used to test for serum androgen in women with moderate-severe hirsutism is total 
testosterone concentration, which is the most sensitive test to establish presence of 
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hyperandrogenemia. Elevated insulin levels and elevated androgen levels both inhibit hepatic 
production of sex hormone-binding globulin (SHBG), which is a glycoprotein that binds to 
testosterone and estrodiol. Serum dehydroepiandrosterone sulfate ester (DHEA-S) test is added when 
there is a concern regarding an androgen secreting tumor. Fifty to ninety percent of women with PCOS 
have an elevated androgen level that is either being secreted by the ovaries, adrenal cortex or both.  
Other causes of hirsutism are drugs, congenital adrenal hyperplasia (most often 21-hydroxylase 
deficiency), hyperthecosis, ovarian tumors, adrenal tumors, severe insulin resistance syndromes, 
hyperprolactinemia and Cushing's syndrome.  
Before polycystic ovarian syndrome is diagnosed other causes need to be eliminated.9 Other 
reasons for infertility also need to be assessed before starting a pregnancy enhancement treatment 
option. Some common causes of infertility (the most common to least) are ovulatory disorders, 
endometriosis, pelvic adhesions, tubal blockage, other tubal abnormalities, and hyperprolactinemia.8
Clomiphene citrate (CC) has been used as first-line treatment for infertility in women with 
PCOS for 40 years. CC is uncomplicated to administer and manage and has been proven to be an 
effective low cost treatment with limited dose dependent side effects. It induces ovulation in 
oligomenorrheic women and has been used to treat anovulatory infertility. 6 CC’s mechanism is to 
exert an antiestrogenic action 7 on the hypothalamas 5thereby increasing7 the gondadotropin releasing 
hormone pulse frequency 5 and the concentration of follicle stimulating hormone and luteinizing 
hormones which increase ovarian follicles until ovulation is reached.7 A common complication that has 
been proven in multiple studies has been the discrepancy between ovulation rates of 60%-85% and 
pregnancy rates of 30%-40%. The reason for this discrepancy is unknown. It could possibly be due to 
CC’s antiestrogenic effect on the cervix and endometrium which causes an increase in cervical mucus 
and risk of subclinical pregnancy, and a thinning of the endometrial layer. 5 CC also has an influence 
  
                                                 
9  
8  
 10 
on uterine blood flow, tubal transport and oocyte quality and maturity.7 This combination leads to a 
hostile environment for sperm transport and implantation. 
Metformin is a biguanide oral antihyperglycemic agent used to treat type 2 diabetes mellitus 5, 
and has recently been used as a second line treatment for CC resistant infertility in women with PCOS. 
Its mechanism of action is to lower blood glucose levels by inhibiting hepatic glucose production and 
by increasing peripheral glucose uptake, which can reduce peripheral insulin concentrations and 
improve glucose tolerance and metabolism.5 It is also a low cost treatment with limited side effects and 
simple administration and management. It too has been proven to improve ovulation rates6, and 
chemical and biochemical features of PCOS.7 Hyperinsulinemia may contribute to hyperandrogenism 
and infertility; therefore, agents which increase insulin insensitivity and reduce insulin levels may be 
necessary.5  
Laparoscopic ovarian diathermy is a second line treatment for anovulation  
in the CC resistant population.7 Also gonadotropin treatment and in vitro fertilization (IVF) have been 
considered useful.5 
 Although clomiphene citrate is used as first-line therapy for the induction of ovulation and the 
achievement of pregnancy in women who have polycyctic ovarian syndrome, the use of metformin 
may be a more reasonable and responsible first-line option, as it addresses secondary effects of PCOS 
(i.e. hyperinsulinemia and insulin resistance).  
Methods 
An extensive literature search was performed using the following search engines: Medline 
(Ovid), PubMed, and CINAHL (EBSCO), and the following search terms: Metformin, infertility, 
PCOS, pregnancy, clomiphene, and ovulation. A total of thirteen articles were located under the above 
search terms and five of those published articles studied metformin versus clomiphene citrate (CC) as a 
first-line therapy for induction of ovulation and the achievement of pregnancy in anovulatory afertile 
women with PCOS. Inclusion criteria were adult women of all races and body mass index (BMI), 
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English only articles, metformin as first line treatment versus clomiphene citrate or both, afertile 
(primary or secondary) and anovulatory women with PCOS. Exclusion criteria were metformin 
compared to surgical intervention (laparoscopic ovarian diathermy), metformin compared to other 
medication treatment, metformin studied against placebo only, metformin alone studied as first line 
therapy, gonadotropin treatment and treatment with IVF, meta analysis and systematic reviews.  
Results 
After inclusion and exclusion criteria were applied five studies remained which met the 
necessary parameters. The five studies compared metformin or extended-release metformin, to 
clomiphene citrate or the combination metformin and clomiphene citrate as first-line therapy for the 
induction of ovulation and pregnancy in afertile anovulatory women with PCOS. The average sample 
size was 100 patients, with one outlier which included 628 patients. The largest study was also the only 
Prospective Parallel Randomized, Double-Blinded, Double-Dummy Controlled Clinical Trial. Two 
others were randomized, nonblinded, control studies. One was a multi-center, nonrandomized 
prospective control studies. And one was an observational comparative study.  
Zain et al and Legro et al were two studies which were randomized. Both compared 
clomiphene citrate, metformin and a combination of metformin and clomiphene citrate. Zain et al 
randomly assigned 115 Asian female patients to one of the three groups. Legro’s et al study also 
randomly divided 626 subjects into three groups. Zain et al, however, used the extended release 
metformin to minimize the side effects of metformin. 
The Zain et al study subjects were divided into three groups. Group 1 consisted of 38 patients 
who received 500 mg of metformin three times daily, group 2 consisted of 39 patients who received 50 
mg of clomiphene citrate (CC) at an incremental dose (max dose 200 mg) and group 3 consisted of 38 
patients who received both CC and metformin. The ovulation rate in Group 1, using metformin only, 
was 23.7%, in Group 2, using CC only, the rate was 59%, and in the combination group, Group 3, the 
ovulation rate was 68.4%. The pregnancy rates were translated similarly among the different groups; 
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7.9%, 15.4% and 21.1%, respectively. The live birth rate was the same in the metformin group and the 
CC group as the pregnancy rate percentage. In Group 3, the combination group, the live birth rate 
dropped to 18.4%, which was decreased to 21.1% pregnancy rate. There were no multiple pregnancies 
in any of the groups (see Table 1). 
The Legro et al study also divided the subjects into three groups. Group 1 initially received 500 
mg of extended release metformin, increasing the dose to a maximum of four 500 mg tablets (two 
tablets twice daily) for a total of 2000 mg. The second group received 50 mg of clomiphene citrate 
starting on day 3 and continuing treatment for five days. This dose was maintained if ovulation was 
documented. Otherwise, the dose was increased by one 50 mg tablet a day per treatment cycle (once a 
month) to reach a maximum of 150 mg. In the Legro study the percentage of live birth rates in Group 1 
was 7.2%, Group 2 the rate was 22.5% and in Group 3 the rate is 26.8%. The P value in the 
combination group was P<0.001.The rate of multiple pregnancies was 6.0% in the clomiphene group, 
0% in the metformin group and 3.1% in the combination group. The rate of spontaneous abortion in 
the first trimester did not differ significantly among the groups. Conception rate among participants 
who ovulated was significantly lower in the metformin group (21.7%) than either Group B or Group C 
(39.5%, P=0.002 and 46.0%, P<0.001, respectively).  Adverse events rate were the same in all three 
groups. Although in the metformin group, GI symptoms were more frequent and vasomotor and 
ovulatory symptoms were less frequent than in the clomiphene group (see Table 1).    
Another study comparing clomiphene citrate, metformin, or combination therapy as first-line 
treatment for ovulation induction and achievement of pregnancy was the Neveu et al study. This was 
an observational comparative trial that included 154 women with PCOS. The subjects were divided 
into three groups. Group 1, using CC only, consisted of 56 patients who received 50 mg of CC daily 
from days 5-9 of the cycle then titrated up by 50 mgs per cycle until they ovulated (maximum dose 
was not stated). Group 2 consisted of 57 patients who received 500 mg of metformin three times daily. 
Metformin was started at 250 mg three times daily for a week to reduce side effects then increased 
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progressively to 500 mg three times a day. The dose was increased to 1000 mg twice a day if ovulation 
had not occurred; otherwise the dose was 1500 mg. Patients who could not tolerate the side effects 
decreased their dose. The third group consisted of 41 patients who received both medications.  In the 
third group, Clomiphene citrate was added after 2 or 3 months after the start of metformin use if 
ovulation had not occurred. Ovulation rate in the CC group was 50% compared to 75.4% in the 
metformin group and the combination group had an ovulation rate of 63.4%. Pregnancy rates in all 
three groups were (35.7%, 45.6%, and 31.7%, respectively). The spontaneous abortion rate for CC was 
15%, metformin was 19.2%, and the combination therapy was 30.7%. A secondary analysis looked at 
metformin, CC, or combination therapy at 6-9 months, 9-12 months and 12 plus months.  
The Palomba et al trial was a parallel randomized, double-blinded, double-dummy control 
clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation 
induction in non-obese anovulatory women with polycyctic ovary syndrome. One-hundred participants 
were divided into to randomized groups. Group A was given 850 mg of metformin twice daily plus 
placebo and Group B was given 150 mg of CC plus placebo for 5 days starting at the third day of 
progesterone-induced withdrawal. The duration of the treatment was 6 months. Women who did not 
achieve ovulation in groups A and B at the six month mark were administered both metformin and CC, 
which ever one they were not on originally, at the same doses described above (cross-over). Women 
who did not achieve pregnancy as the outcome but who did ovulate were treated with three trials of 
controlled ovarian stimulation followed by intrauterine insemination before assisted reproductive 
techniques. The ovulation and pregnancy rates did not vary significantly in each group with 62% 
ovulating in the metformin group and 67% ovulating in the clomiphene group. Pregnancy per 
ovulatory cycle, however, was higher in the metformin group (15.1%) compared to the clomiphene 
group (7.2%) with a P=0.045. The spontaneous abortion rates comparatively were 9.7% in the 
metformin group and 37.5% in the clomiphene group with a P=0.045. The live birth rate was also 
higher in the metformin group at a rate of 83.9% versus 56.5% (P=0.07). None of the women had 
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multiple pregnancies in either group.  After 6 months of treatment the cumulative pregnancy rate was 
68.9% versus 24.0% (P<0.001) for metformin and clomiphene, respectively. 
  
The Palomba2 et al multi-center nonrandomized, prospective, controlled study included 80 
infertile anovulatory patients with PCOS. The study divided the women into two groups: an 
experimental group (metformin treatment) and the control group (clomiphene citrate). The 
experimental group (Group 1) was treated with 850 mg daily of metformin for the first week and then 
increased to one tablet twice daily. The control group (Group 2) received 50 mg clomiphene citrate 
starting on day 3 of progesterone induced withdrawal bleeding and it was continued for 5 days. The 
dose was either left at 50 mg or incrementally increased by 50 mg until ovulation was achieved or a 
maximum dose of 250 mg was reached. Patients who did not ovulate once the maximum dose was 
reached were considered CC-resistant. Otherwise, the patients continued with the treatment for six 
ovulatory cycles. There was no significant difference in ovulation between Group 1 or Group 2 (55.4% 
vs. 59.8%, respectively; P=0.396), pregnancy (10.8% vs. 11.2%, respectively; P=0.888) and 
spontaneous abortion (19.5 vs. 26.3%, respectively; P=0.530).  
 
Discussion 
The purpose of this review is to decide whether metformin should be used as a first-line 
treatment in the induction of ovulation and the achievement of pregnancy in anovulatory infertile 
women with PCOS through an extensive literature review. Since some trials were randomized, one 
non-randomized and another was observational non-randomized, it was difficult to compare trials 
head-to-head.  Each article was reviewed and graded if possible, on the following criteria: the study 
design, (i.e. randomized, double-blinded, controlled, observational, and comparative), sample size, 
dosage, weight, other infertility factors, and age.    
Each study had an adequate sample size of an average of 100 participants with one outlier of 
626 participants. The Palomba et al study was the most well organized study in this review. The 
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method and randomization was described and it was a double-blinded trial. Participants lost to follow-
up were adequately accounted for. The total JADAD score was four, losing one credit point for not 
describing the method for double-blinding the study. In the observational comparative by Neveu et al, 
the subjects were given the treatment option of metformin, clomiphene, or both. The patients had full 
disclosure as to the side effects and benefits of the drug options. Therefore, many overweight subjects 
chose metformin instead of clomiphene due to possible weight loss. This issue of allowing patients to 
choose their group may have led to an imbalance between the groups with most of the obese patients 
choosing to be in the same group causing a distortion in the results.   
The study design in the observational comparative trial is relevant because the particular study 
design used by the investigators may have resulted in substandard results. For instance, in the 
combination therapy group (Group 3) the patients were started on metformin, and if ovulation did not 
occur within two to three months, they were started on clomiphene citrate. The patients stayed in 
Group 3 whether or not they had started taking clomiphene citrate in combination with metformin. 
This method creates the risk that the reader would draw an incorrect inference from the data because an 
unknown number of participants in Group 3 could have been treated with metformin only, making the 
results indistinguishable from the metformin only group.  
The Zain et al and Legro et al trials did not blind investigators or patients, which subjected both 
parties to bias. Almost all participants in the Zain et al study were Asian Malay and less than 5% 
showed signs of clinical hirsutism, which is consistent with other studies examining PCOS in Asian 
women, but not representative of the general population of women with PCOS. A very selective 
population with unique qualities inherent to that particular population limits the study substantially. 
Metformin, with its antihyperandrogenemic qualities, could possibly not be as effective in Asian 
Malay women. Investigators were subjected to bias in the Palomba2 study as well. Variability also 
existed in the initiation and conclusion of medication because it was a clinic based trial and in multiple 
centers.   
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Anovulation and infertility are two complex hormonal and biological conditions that can affect 
women in their reproductive years. Some common causes of infertility (the most common to least) are 
ovulatory disorders, endometriosis, pelvic adhesions, tubal blockage, other tubal abnormalities, and 
hyperprolactinemia.8 In the Zain et al study, women were not evaluated for other clinical explanations 
of infertility like tubal patency and tubal disease, which account for 22% of women who are infertile.8
Obesity is associated with increased insulin resistance, which causes chronic anovulation. 4 
Moreover, treating infertility with diet and lifestyle modifications would be extremely beneficial in 
obese women with PCOS. However, weight loss is a challenge for most women. Therefore, since 
insulin-lowering and insulin-sensitizing medications like metformin decrease insulin resistance, a 
beneficial effect on ovulation and fertility in obese women with PCOS can be achieved.  
 
Therefore, the results could be distorted by including women who may have had a cause of infertility 
other than an ovulation disorder.  
In the Legro et al study, the patients were morbidly obese with the highest BMI in the group 
who received CC only. There was a higher degree of pregnancy related adverse events in the CC only 
and combination therapy groups, which could be related to the higher BMI in these groups. In the 
Neveu et al study, the metformin group with a higher mean BMI also had a statistically significant 
increase in ovulation rate over the CC only group. The Neveu et al study observed that the ovulation 
rate was similar between the two groups when the BMI was <27 or >35, but with a BMI of between 27 
and 35, the patients ovulated more on metformin. This could be due to increased difficulty to overcome 
insulin resistance with a higher BMI. In the Zain et al trial the women were morbidly obese with a 
mean BMI of all three groups of 33.3 and the end result, although statistically insignificant, showed a 
higher rate of live births on CC. The Palomba et al study excluded obese women. This could be due to 
the fact that in the general population non obese women have fewer propensities for infertility and 
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pregnancy complications than obese women and the investigators thought this would eliminate obesity 
related causes for infertility. Metformin was shown to be superior to CC in this study. As a side note, 
this was the only study that used ovarian stimulation followed by intrauterine insemination on women 
who did not achieve pregnancy. The study failed to disclose the number of patients who underwent this 
procedure or under which group they were allocated.  
Clomiphene citrate is typically prescribed at a 50 mg daily dose for five days. It is increased in 
increments of 50 mg each month until ovulation occurs or a maximum dose of 150 mg has been 
reached. In the Palomba et al study, the investigators started the dose at 150 mg. CC affects the 
endometrium, cervical mucus and uterine blood flow, which can cause a hostile environment for 
implantation. The initial use of such a high dose could have had a deleterious effect. In fact, in the 
Palomba2 et al and Neveu et al study, there was no change in the efficacy of CC at 50 mg versus 200 
mg. Also in the Palomba2 et al study, there was no effect on ovulation or pregnancy in a single case 
once 200 mg was reached. Immediate release metformin was used in all studies but the Legro et al 
study. Therefore, the extended release metformin could have less effect on women with PCOS to 
induce ovulation and pregnancy.  
Other limitations that varied across all the studies were documentation relating to the frequency 
of sexual intercourse, monitoring of ovulation, number of months a female was anovulatory or number 
of days between menses (oligoamenorrhea), previous ovulation induction drug treatment, glucose 
intolerance, partners with sperm abnormalities and live birth. The Palomba et al, Palomba2 et al and 
the Legro et al studies required their participants to track the frequency of sexual intercourse. The other 
two studies did not, which obviously can affect the outcome of pregnancy. The definition of 
anovulation varied from absence of menses for greater than six months to greater than eight months 
and oligoamenorrhea ranged from menses occurring greater than every 35 days or less than nine 
months a year. Some of the patients in this study may have ovulated one month in the last year, and 
others may have ovulated ten times over the past year. Obviously, increased ovulation increases 
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pregnancy odds. In the Legro et al study, more than 50% of the participants had previously been on 
ovulation induction treatment, which can potentially increase the odds of pregnancy. In the Neveu 
study, the researchers did not exclude women who were glucose intolerant or whose partners had 
sperm abnormalities. The degree of glucose intolerance may have had a greater effect on the efficacy 
of metformin in treating anovulatory infertile women. The author of the study noted that lower fasting 
blood sugars and lower systolic blood pressure is predictive of better ovulatory response on CC. The 
metformin group, however, had lower testosterone and androstenedione.  
Besides pregnancy and ovulation rates, the Legro et al and Zain et al studies measured 
metabolic and hormonal effects associated with the three groups (CC, metformin or both therapies) 
initially and at six months. The Legro et al study measured other outcomes like testosterone (as 
metformin also has an antiandrogenemic effect), BMI and sex hormone-binding globulin. Although the 
conception rate among the women who ovulated in the metformin group was lower than the other 
groups, the baseline metabolic and hormonal laboratory results were significant when compared to the 
results at the end of the study. When each particular group is compared to the remaining groups, a 
decrease in BMI and total testosterone was observed.  Also, a significant increase in sex hormone-
binding globulin levels, with a corresponding decrease in free androgen index was found when each of 
these groups was compared. In the clomiphene group, there was an increase in BMI, insulin levels, and 
insulin resistance, although all of these were insignificant. However, there was a significant increase in 
sex hormone-binding globulin and a decrease in free androgen. The combination group had similar 
results to the metformin group which were significant for all comparisons. The Zain et al study did not 
see a notable difference in body weight or waist-to-hip measurement at three or six months of 
treatment with metformin, although there was a significant increase in menstrual cycle regularity from 
three months to six months. In this study, even though there was a decrease in BMI in the metformin 
only group, this did not change the outcome of pregnancy. In the combination group, the live birth rate 
was high, although statistically insignificant, with the additional positive secondary outcomes of lower 
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BMI and insulin sensitivity. Although this was not the purpose of these studies or this review, 
examining the effects metformin has on metabolic and hormonal levels can be the basis for a defense 
of the decision to use metformin to treat infertility in women with PCOS.  
Examining the live birth rate is an important consideration when comparing the efficacy of 
metformin to CC, as this is the goal of women who seek pregnancy enhancement treatment. However, 
only three studies reviewed had live births as the outcome: Legro et al, Zain et al and Palomba et al. 
The other two trials only used ovulation and conception as their outcome.  
The studies mentioned in this review were limited by the study design and method. In order to 
avoid these limitations, more blinded, randomized trials need to be implemented. These improvements 
on the study design will lead to more conclusive results. The patient population should be more 
heterogeneous and representative of women with PCOS. These studies should compare the efficacy of 
metformin, CC, and combination therapy on live birth rates in obese and non obese women. Additional 
studies need to be performed to analyze the long term effects of metformin to achieve pregnancy. As 
for more studies surrounding the effects of clomiphene citrate, examining the long term effects of CC 
on pregnancy (i.e. gestational diabetes) and health of mothers (i.e. type 2 diabetes) would be beneficial.  
 
Conclusion 
 
Although clomiphene citrate is the medication currently used as first-line therapy for fertility 
treatment in women with PCOS, the scope of its effects are limited only to ovulatory issues. The 
results of the studies in this review indicated that metformin may increase ovulation, pregnancy and 
live birth outcomes in certain circumstances. In addition to these outcomes, the results showed that 
metformin also addresses other contributing factors of PCOS, such as hyperinsulinemia. However, the 
studies in this review did not render conclusive results regarding these particular issues. If these results 
could be confirmed by further studies, metformin may be a more reasonable and responsible option in 
certain scenarios where the secondary effects of the drug would be beneficial to the patient. 
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Tables 
 
Table I: Comparing Metformin to Clomiphene Citrate, or combination therapy in each of the five 
studies 
 
 
 
 
 
 
 
 
 
 
 
 
  Legro Zain Neveu Palomba Palomba2 
Live Birth Rate: clomiphene 22.5% 15.4% na 68.9% na 
Live Birth Rate: metformin 7.2% 7.9% na 34.0% na 
Live Birth Rate: clomiphene and metformin 26.8% 18.4% na na  na 
            
rate of multiple pregnancies: clomiphene 6.0% 0.0% 0.0% 0.0% <1 
rate of multiple pregnancies: metformin 0.0% 0.0% 0.0% 0.0% 0.0% 
rate of multiple pregnancies: combination 3.1% 0.0% 0.0% 0.0% 0.0% 
            
first-trimester spontaneous abortions clomiphene 22.6% 0.0% 15.0% 9.7% 48.6% 
first-trimester spontaneous abortions: metformin 40.0% 0.0% 19.2% 37.5% 67.9% 
first-trimester spontaneous abortions: both 30.0% na 30.7%  Na na 
            
conception rate among women who ovulated: clomiphene 39.5% 15.4% 45.6% Na  11.2% 
conception rate among women who ovulated metformin 21.7% 7.9% 35.7%  Na 10.8% 
conception rate among women who ovulated: both 46.0% 21.1% 37.0%  na   
            
ovulation rate: clomiphene na  59.0% 50.0% 62.9% 59.8% 
ovulation rate: metformin na  24.0% 75.4% 67.0% 55.4% 
ovulation rate: clomiphene and metformin na  66.6% 63.4%  na na  
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Author/  Title/ Journal Yr.  
published 
Patients/  
Population 
Intervention Comparison Outcome(s) Study type Validity 
(Jadad 
score) 
Stefano Palomba et al/ 
Prospective Parallel 
Randomized, Double-Blind, 
Double-Dummy Controlled 
Clinical Trial Comparing 
Clomiphene Citrate and 
Metformin as the First-Line 
Treatment for Ovulation 
Induction in Nonobese 
Anovulatory Women with 
Polycycstic Ovarian 
Sydnrome/Journal of 
Clinical Endocrinology and 
Metabolism 
July 2005 
 
100 Non obese   
Anovulatory 
Women with 
PCOC 
Metformin as 
first line 
therapy 
Clomiphene 
Citrate PLUS 
placebo and 
Metformin  
PLUS placebo  
Ovulation, 
pregnancy, 
spontaneous 
abortion, 
live birth 
rates 
Prospective 
Parallel 
Randomized, 
Double-Blind, 
Double-Dummy 
Controlled 
Clinical Trial  
4 
Neveu et al/ Comparison of 
clomiphene citrate, 
metformin, or the 
combination of both for 
first-line ovulation 
induction and achievement 
of pregnancy in 154 women 
with polycystic ovary 
syndrome/American 
Society for Reproductive 
Medicine 
January 
2007 
154 Infertile 
women with 
PCOS 
Metformin CC, Metformin 
or both  
Ovulation 
and 
pregnancy 
Observational 
comparative 
study 
 
Legro et al/ Clomiphene, 
Metformin or Both for 
Infertility in the Polycystic 
Ovarian Syndrome/The 
New England Journal of 
Medicine 
Feb 8, 2007:  
626 people 
626 
anovulatory 
women with 
PCOS 
Metformin Extended release 
Met plus 
placebo, CC plus 
placebo, and 
metformin and 
CC  
Primary 
outcome live 
birth rate 
and the 
secondary 
outcome 
ovulation  
Randomized 
control study 
 
Zain et al/ Comparison of 
clomiphene citrate, 
metformin, or the 
combination of both for 
first-line ovulation 
induction, achievement of 
pregnancy and live birth in 
Asian women with PCOS/ 
American Society of 
Reproductive Medicine 
Feb 2009 115 
anovulatory 
afertile Asian 
women with 
PCOS  
Metformin Comparing  CC, 
Metformin or 
both therapies 
Ovulation, 
pregnancy 
and live 
birth 
Randomized 
controlled study 
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Palomba et al/ Clomiphene 
citrate versus metformin as 
first line approach for the 
Treatment of Anovulation 
in Infertile Patients with 
Polycystic Ovary Syndrome 
 
 
June 26, 
2007 
 
 
80 infertile 
anovulatory 
women with 
PCOS 
 
 
Metformin 
 
 
Metformin 
versus CC   
 
 
Ovulation, 
pregnancy 
and 
spontaneous 
abortion 
 
 
Multicenter, 
nonrandomized 
prospective 
controlled study 
 
 
Table II: Comparison of Literature on the First-Line Treatment of Metformin in Anovulatory Afertile 
Women with PCOS 
 
 
 
